Source comparison
CJC-1295 Typically Administered in Research: Comparison
CJC-1295 with DAC 1–2mg per injection Once weekly 6–8 days Gradual elevation over 48–72 hours, sustained 10–14 days Long-term body composition studies, extended metabolic intervention trials Best for studies requiring stable GH elevation without frequent dosin
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC
- 1–2mg per injection
- Once weekly
- 6–8 days
- Gradual elevation over 48–72 hours, sustained 10–14 days
- Long-term body composition studies, extended metabolic intervention trials
- Best for studies requiring stable GH elevation without frequent dosing. Simplifies compliance but limits acute response measurement
- CJC-1295 without DAC (Mod GRF 1-29)
- 100–200mcg per injection
- 2–3 times weekly
- 30 minutes
- Acute spike within 15–30 minutes, returns to baseline within 2–3 hours
- Acute GH response studies, combination protocols with GHRP peptides
- Preferred when measuring immediate GH secretion dynamics or combining with other secretagogues. Requires precise timing
- CJC-1295 + Ipamorelin (stacked)
- 100mcg CJC + 200mcg Ipamorelin
- 2–3 times weekly (same injection)
- 30 min (CJC non-DAC) / 2 hours (Ipamorelin)
- Synergistic peak within 20–40 minutes
- Body recomposition research, sleep quality studies, recovery protocol trials
- Combination amplifies GH pulse without proportionally increasing cortisol or prolactin. Widely used in performance research